Metamark makes Blume-Jensen CSO
This article was originally published in Clinica
Personalised medicine expert Metamark Genetics has appointed Peter Blume-Jensen to the position of chief scientific officer. Dr Blume-Jensen worked from 2001 until 2008 as department head at EMD Serono and later at Merck Research Laboratories, Merck & Co. Since 2008, he worked as executive director, external scientific affairs and vice-president of Daiichi Sankyo’s Research Institute. Cambridge, Massachusetts-based Metamark is currently developing prognostic tests that enable the personalised treatment of cancer patients.